Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 215

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 215
---
96,099)$(8,721)Other comprehensive income (loss), net of tax:    Change in unrealized gain (loss) on marketable securities available-for-sale364 (1,457)Cumulative foreign currency translation adjustments1,714 (808)Total other comprehensive income (loss)2,078 (2,265)Total comprehensive loss$(94,021)$(10,986)

See accompanying notes.

6

Table of Contents

Dynavax Technologies Corporation 

Condensed Consolidated Statements of Stockholders’ Equity 

(In thousands) 

(Unaudited) 

 Common Stock Preferred StockThree Months Ended March 31, 2025SharesPar AmountSharesPar AmountAdditionalPaid-In CapitalAccumulatedOtherComprehensive (Loss) IncomeAccumulated Deficit TotalStockholders' EquityBalance at December 31, 2024125,450$125 -$- $1,504,671 $(4,722)$(903,275)$596,799 Issuance of common stock upon exercise of stock options6701--6,503--6,504Issuance of common stock upon release of restricted and performance stock awards, net of statutory tax withholdings1,3692--(11,141)--(11,139)Issuance of common stock under Employee Stock Purchase Plan89---835--835Repurchase of common stock(3,881)(4)--(29,042)--(29,046)Unwind of capped call options (Note 7)----46,554--46,554Stock compensation expense----14,455--14,455Total other comprehensive income-----2,078-2,078Net loss------(96,099)(96,099)Balances at March 31, 2025123,697$124 -$- $1,532,835 $(2,644)$(999,374)$530,941            Common StockPreferred Stock        Three Months Ended March 31, 2024Shares Par AmountSharesPar AmountAdditionalPaid-In CapitalAccumulatedOtherComprehensive LossAccumulated Deficit TotalStockholders' EquityBalances at December 31, 2023129,530$130 -$- $1,554,634 $(2,108)$(930,584)$622,072 Issuance of common stock upon exercise of stock options240---1,635--1,635Issuance of common stock upon release of restricted stock awards